Drug Discovery Online Home Page

BMG LABTECH - Microplate Readers Specialist

Wed, 30 Aug 2006 19:21:00 GMT

BMG LABTECH offers the most complete line of microplate readers available. These have been designed to provide you with comprehensive solutions for life science, drug discovery, development and academic research

Pall: provider of filtration, purification and separation technologies

Thu, 28 Aug 2003 13:19:00 GMT

The life sciences industry is both driven and united by its need for speed to market, product reliability and economics. Pall Corporation's leading edge technologies and services play an essential and pivotal role in this industry's ability to achieve these goals...

Cephalon Submits NUVIGIL Supplemental New Drug Application For The Treatment Of Excessive Sleepiness Associated With Jet Lag Disorder

Wed, 01 Jul 2009 10:37:14 GMT

Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL® (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel

Application Note: Evaluation Of PARP Inhibitors: Performed On BMG LABTECH's FLUOstar Omega

Thu, 02 Jul 2009 03:51:00 GMT

Poly ADP-ribosylation is a post-translational modification of proteins that plays a crucial role in regulating DNA repair. Poly (ADP-ribose) polymerase (PARP) transfers ADP-ribose to itself and other nuclear proteins such as histones. The substrate for that reaction is NAD+. By BMG LABTECH, GmbH

Raptor Pharmaceuticals To Collaborate With Roche On Therapeutic Delivery Across Blood-Brain Barrier

Tue, 09 Jun 2009 13:14:00 GMT

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has entered a collaboration and licensing agreement with Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic delivery across the blood-brain barrier, ("BBB") starting with Raptor's proprietary NeuroTrans(TM) BBB transporter platform. Under terms of the agreement, Roche will fund studies of select molecules attached to Raptor's proprietary NeuroTrans(TM), a derivative of the receptor-associated protein ("RAP").

Flyer: Quality Assurance/Quality Control (QA/QC)

Tue, 09 Jun 2009 14:33:49 GMT

The objective of PYRAMID Laboratories, Inc. (PYRAMID's) Quality Assurance (QA) program is to ensure that all manufacturing processes and data collected are scientifically valid, of known precision and accuracy and properly documented.

MDS Pharma Services Expands Drug Discovery Capability In Asia

Mon, 08 Jun 2009 11:10:00 GMT

MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, today announced that a renovation and expansion of its discovery pharmacology operation in Taiwan is under way to serve the growing global demand for work performed in Asia

BioSeek And EPA Expand ToxCast™ Contract

Tue, 30 Jun 2009 13:01:00 GMT

BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery, announced today that the United States Environmental Protection Agency (EPA) will utilize BioSeek's BioMAP Systems technology to profile the biological effects of compounds in a second phase of the agency's ToxCast program.

Certara Expands Presence In Drug Discovery And Development Markets in China And Taiwan

Wed, 01 Jul 2009 00:00:00 GMT

Certara, a global, translational sciences company formed by the acquisition of Pharsight Corporation by Tripos, recently announced expanded investment and presence in China and Taiwan in support of drug discovery and development efforts, and also confirmed that Tri-I Biotech, Inc.

GE Healthcare And Geron Announce Exclusive Global Agreement To Commercialize Stem Cell Drug Discovery Technologies

Tue, 30 Jun 2009 11:30:00 GMT

GE Healthcare, a unit of General Electric Company, and Geron Corporation today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening.

Optimata To Collaborate With Teva Pharmaceutical Industries Ltd. On Clinical Development Of Solid Tumor Cancer Drugs

Tue, 30 Jun 2009 11:00:00 GMT

Optimata Ltd. announced recently that it has signed a collaboration agreement with Teva Pharmaceutical Industries Ltd. focused on clinical development of drug candidates for solid tumor cancers

Novocell Obtains U.S. Patent For Drug Screening Human Embryonic Cell Derived-Endoderm Cells

Wed, 03 Jun 2009 12:30:00 GMT

Novocell, Inc., a stem cell engineering company, recently announced that it has received U.S. Patent No. 7,541,185 with method claims covering the use of endoderm cells derived from human embryonic stem cells (hESCs) for drug discovery

Data On Investigational Drug TMC207 For Treatment Of MDR -Tuberculosis, Published In New England Journal Of Medicine

Wed, 03 Jun 2009 11:50:00 GMT

Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine recently.

Accelrys Releases New Modeling And Simulation Software For Life Science Researchers With Discovery Studio 2.5

Mon, 29 Jun 2009 09:47:00 GMT

Accelrys, Inc., a leading provider of scientific business intelligence software and services, announced the release of Discovery Studio 2.5, the most advanced computational chemistry and biology software environment for drug discovery available today

GenScript Raises $15M For Drug Discovery And Development Services Expansion -Kleiner Perkins Invests In Biology CRO Business

Fri, 26 Jun 2009 09:36:00 GMT

GenScript Inc., a world leader in bio-reagent supply and biology CRO service announced recently that it has received a $15 million venture funding for the expansion of its biology services in drug discovery and development

New Nanoparticles Could Revolutionize Therapeutic Drug Discovery

Wed, 24 Jun 2009 08:56:00 GMT

A revolutionary new protein stabilisation technique has been developed by scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) which could lead to 30 per cent more proteins being available as potential targets for drug development - opening up exciting possibilities in drug discovery

White Paper: Research Efficiency In Hard Times: It's Time To Adapt

Tue, 23 Jun 2009 05:03:00 GMT

Nobody likes hard times, but they do have one redeeming quality: They focus attention on areas neglected in good times. The need for greater efficiency is a prime example, especially for small drug development companies. Even in the best of times, they must cope with the formidable combination of high costs, long timelines, and low success rates. And when hard times come, they feel it first and most acutely. These companies should be the first to ask: Is there a better way? By Michael Rosenberg, M.D., MPH, Life Science Leader magazine

Pharsight Launches Phoenix WinNonlin As Cornerstone Of New Software Platform For Model-Based Drug Development

Tue, 02 Jun 2009 12:00:00 GMT

Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, recently announced the launch of Phoenix WinNonlin, the next generation of the company's industry-standard software tool for pharmacokinetic and pharmacodynamic (PK/PD) modeling and noncompartmental analysis

French Researchers Accelerate Biomarker Research With QTRAP 5500 Mass Spectrometry Systems

Tue, 02 Jun 2009 11:30:00 GMT

Applied Biosystems, a division of Life Technologies Corporation, recently announced that scientists at bioM�rieux, a world leader in the field of in vitro diagnostics, and the Institute of Analytical Sciences of the University of Lyon in France are collaborating on research to advance the discovery of biomarkers that can be used to diagnose or monitor disease

Concert Pharmaceuticals And GlaxoSmithKline Form Alliance To Develop Novel Deuterium Modified Drugs

Tue, 02 Jun 2009 07:00:00 GMT

Concert Pharmaceuticals and GlaxoSmithKline announced recently that they will collaborate to develop and commercialize deuterium-containing medicines

Adimab Launches Novel Antibody Discovery Platform And Announces Discovery Programs With Merck And Roche

Tue, 16 Jun 2009 11:00:00 GMT

Adimab, Inc., an emerging leader in the discovery of fully human antibodies, today announced the launch of a unique human antibody discovery platform based on the first fully synthetic human pre-immune IgG repertoire.

Case Study: Guilty Or Not Guilty: Justice Is Served With XP205 Semi-Microbalance

Tue, 16 Jun 2009 05:10:00 GMT

The independent Forensic Scientific Service (FND) of the State Police in St. Gallen, Switzerland conducts analytical and forensic tests with the aim of detecting proof of suspected crimes such as the illegal possession of drugs. As samples are generally available in powder form and in rather small quantities, an XP205 semi-microbalance was the customer's solution to assist in their delicate weighing tasks. By Mettler-Toledo, Inc.

OPKO Invests In Biotechnology Company With Novel Approach To Developing New Drugs

Mon, 15 Jun 2009 15:07:00 GMT

OPKO Health, Inc. has agreed to make an investment in Cocrystal Discovery, Inc., a privately held biopharmaceutical company focusing initially on the discovery and development of novel antiviral drugs for diseases for which current therapies are not adequate

New Phase 3 Data Continue To Indicate That Wyeth's Investigational 13-valent Vaccine Has The Potential To Broaden Coverage Against Pneumococcal Disease

Thu, 11 Jun 2009 13:17:27 GMT

New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide.

Cutting Edge Information's Latest Therapeutic Area Study Examines Autoimmune Drugs, Classes And Market-Leading Companies

Thu, 11 Jun 2009 07:26:00 GMT

Pharmaceutical business intelligence firm Cutting Edge Information announces the launch of its latest therapeutic area study, which provides forecasts for the autoimmune market.

Gentronix and Apredica Ally To Create Predictive-Toxicology Service

Thu, 11 Jun 2009 06:22:00 GMT

Gentronix Limited, a genotoxicity product and services provider, and Apredica, an ADME-Tox contract research laboratory, recently announced a strategic alliance to provide drug-discovery support services in the area of predictive toxicology.

Datasheet: Biologics Manufacturing

Thu, 11 Jun 2009 05:14:00 GMT

Abbott offers you state-of-the-art Biologics Manufacturing Capabilities, including Smart solutions to process design, analytical characterization and cGMP manufacturing, supporting the development and commercialization of your biopharmaceutical product.

Sealkleen Membrane Filter Cartridges

Thu, 29 May 2008 17:13:00 GMT

Pall SealkleenT membrane filter cartridges are made with either Ultipor N66, Posidyne, or Fluorodyne II membranes with a choice of retention ratings in two high-area sizes.

Datasheet: Mustang® Q XT Ion Exchange Chromatography Capsules

Fri, 22 May 2009 07:01:00 GMT

Mustang Q XT capsules have been designed for optimum membrane chromatography performance, providing scalability from process development through to full scale manufacturing.

Datasheet: Q And S HyperCel™ Chromatography Sorbents

Fri, 22 May 2009 06:13:00 GMT

Q and S HyperCel sorbents are composed of a rigid cellulose matrix that has excellent flow properties and generates low backpressure, compatible with the needs of large-scale protein production.

Realize Your Cytotoxic Agent's Unique Potential

Mon, 18 May 2009 12:00:00 GMT

Product Brochure: Cytotoxic Manufacturing

Add A Powerful Ingredient To Your Parenteral Manufacturing

Mon, 18 May 2009 11:58:00 GMT

Product Brochure: Parenteral Manufacturing

Flyer: About PYRAMID Laboratories

Wed, 13 May 2009 07:15:00 GMT

PYRAMID Laboratories, Inc. (PYRAMID), established in 1988, is located in southern California, USA. Our facilities are housed in three (3) buildings covering over 50,000 sq. ft.

Flyer: Pharmaceutical Development Services

Wed, 13 May 2009 07:07:00 GMT

The scientific staff at PYRAMID Laboratories, Inc. has more than 30 years of experience across all areas of parenteral formulation and manufacturing. From pre-clinical through clinical and on to commercial manufacturing, PYRAMID focuses on optimizing your product's stability and performance.

Flyer: PYRAMID Laboratories Lyophilization Services

Wed, 13 May 2009 06:27:00 GMT

PYRAMID's goal in the development of a lyophilized drug product is to produce a pharmaceutically elegant and physico-chemically stable product that can be easily reconstituted and administered to the patient. Scientists at PYRAMID have the background and knowledge in lyophilization technology to assist you in reaching that goal for your drug product.

Article: Managing Solid Waste From Single- Use Systems In Biopharmaceutical Manufacturing

Tue, 31 Mar 2009 06:09:00 GMT

The increasing implementation of single-use systems (SUS) in biopharmaceutical manufacturing has been driven by multiple factors including cost reduction, increased flexibility, improved process development time, and reduced capital investment. By H�l�ne Pora and Bruce Rawlings

Article: A Prescriptive Approach To Management Of Solid Waste From Single-Use Systems

Tue, 31 Mar 2009 04:30:00 GMT

In biopharmaceutical manufacturing, the disposal of solid waste from single-use systems is becoming an increasingly important issue. The new focus is driven by several major factors including a broadening range of disposable technologies enabling, in some cases, the installation of completely disposable multistage systems; improved scalability of singleuse components offering production capacities to thousands of liters; and the environmental impact of waste disposal. By Bruce Rawlings and H�l�ne Pora

Article: Environmental Impact of Single-Use And Reusable Bioprocess Systems

Tue, 31 Mar 2009 04:10:00 GMT

Bioprocess manufacturing systems have incorporated single-use/disposable components for more than 50 years and have demonstrated welldefined process benefits from their use (1-6). The environmental impact of single-use technologies, however, has been a major focus of attention only in recent years. By Bruce Rawlings and H�l�ne Pora

Article: Implementing Single-Use Technology In Biopharmaceutical Manufacturing

Tue, 31 Mar 2009 05:55:00 GMT

In biopharmaceutical manufacturing, single-use components and systems can offer distinct advantages over reusable, cleanable systems. Deciding whether to move to a single-use approach, however, depends on many factors. By Weibing Ding and Jerold Martin

Case Study: Introducing Disposable Systems Into Biomanufacturing

Tue, 31 Mar 2009 05:39:00 GMT

Single-use (disposable) systems are being considered and introduced into many biopharmaceutical processes because manufacturers have identified significant benefits they offer over traditional reusable systems. By Mark Fuller and H�l�ne Pora

Article: Applying Good Engineering Practices To The Design Of Single-Use Systems

Tue, 31 Mar 2009 05:21:00 GMT

Significant changes are being incorporated into biopharmaceutical manufacturing processes as a result of drivers such as increasingly strict regulatory demands, reduction of manufacturing costs, and outsourcing to contract manufacturing organizations (CMOs). By Martyn Botterill and Bruce Rawlings

EUDRAPULSE®

Tue, 30 Dec 2008 05:49:00 GMT

EUDRAPULSE® enables rapid, immediate (pulsed) drug release after a defined lag time. A layer composed of drug and organic acid, or its salt, is applied to a core acting as the carrier, which is coated with EUDRAGIT® RL/ RS.

EUDRACOL®

Tue, 30 Dec 2008 05:37:00 GMT

EUDRACOL® gives Pharma Polymers a multi-unit technology that provides targeted drug delivery direct to the colon, with delayed and uniform drug release. The system consists of several layers. At the center is a core containing the active.